Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. [electronic resource]
Producer: 20100520Description: 2373-80 p. digitalISSN:- 1527-7755
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20 -- immunology
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Computer Simulation
- Cyclophosphamide -- administration & dosage
- Disease Progression
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Female
- Health Status Indicators
- Humans
- Kaplan-Meier Estimate
- Lymphoma, B-Cell -- diagnosis
- Male
- Middle Aged
- Predictive Value of Tests
- Prednisone -- administration & dosage
- Proportional Hazards Models
- Prospective Studies
- Risk Assessment
- Risk Factors
- Rituximab
- Time Factors
- Treatment Outcome
- Vincristine -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.